Resmed (RMD) Cash & Equivalents (2009 - 2026)

Resmed (RMD) has 18 years of Cash & Equivalents data on file, last reported at $1.7 billion in Q1 2026.

• Quarterly Cash & Equivalents rose 78.03% year-over-year to $1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 78.03% YoY) and the FY2025 annual result came in at $1.2 billion, up 407.4% from the prior year.
• Cash & Equivalents rose to $1.7 billion in Q1 2026, from $1.4 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.7 billion in Q1 2026 to a low of $201.8 million in Q1 2022.
• A 5-year average of $578.8 million and a median of $253.2 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents decreased 24.98% — and 2025, when it soared 407.4%.
• Tracing RMD's Cash & Equivalents over 5 years: stood at $253.2 million in 2022, then slipped by 16.96% to $210.2 million in 2023, then soared by 148.25% to $521.9 million in 2024, then surged by 171.5% to $1.4 billion in 2025, then increased by 17.18% to $1.7 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.7 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.